menu
    • menu
    [{"orgOrder":0,"company":"Glaceum","sponsor":"Catholic University of Korea | Kyunghee University Medical Center | Korea University Guro Hospital | Samsung Medical Center | Severance Hospital | Inje University | Hallym University Medical Center | The Catholic University of Korea Uijeongbu St.Marys Hos","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Vutiglabridin","moa":"Mitochondrial function","graph1":"Neurology","graph2":"Phase II","graph3":"Glaceum","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glaceum \/ Catholic University of Korea | Kyunghee University Medical Center | Korea University Guro Hospital | Samsung Medical Center | Severance Hospital | Inje University | Hallym University Medical Center | The Catholic University of Korea Uijeongbu St.Marys Hos","highestDevelopmentStatusID":"8","companyTruncated":"Glaceum \/ Catholic University of Korea | Kyunghee University Medical Center | Korea University Guro Hospital | Samsung Medical Center | Severance Hospital | Inje University | Hallym University Medical Center | The Catholic University of Korea Uijeongbu St.Marys Hos"},{"orgOrder":0,"company":"Glaceum","sponsor":"Seoul National University Hospital | Seoul National University Bundang Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Vutiglabridin","moa":"Mitochondrial function","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Glaceum","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glaceum \/ Seoul National University Hospital | Seoul National University Bundang Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Glaceum \/ Seoul National University Hospital | Seoul National University Bundang Hospital"},{"orgOrder":0,"company":"Glaceum","sponsor":"Seoul National University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"HGR4113","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase I","graph3":"Glaceum","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glaceum \/ Seoul National University Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Glaceum \/ Seoul National University Hospital"},{"orgOrder":0,"company":"Glaceum","sponsor":"Gangnam Severance Hospital | Seoul National University Bundang Hospital | Korea University Anam Hospital | Seoul National University Hospital | SMG-SNU Boramae Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"HSG4112","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Glaceum","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glaceum \/ Gangnam Severance Hospital | Seoul National University Bundang Hospital | Korea University Anam Hospital | Seoul National University Hospital | SMG-SNU Boramae Medical Center","highestDevelopmentStatusID":"8","companyTruncated":"Glaceum \/ Gangnam Severance Hospital | Seoul National University Bundang Hospital | Korea University Anam Hospital | Seoul National University Hospital | SMG-SNU Boramae Medical Center"},{"orgOrder":0,"company":"Glaceum","sponsor":"Kyungpook National University Hospital | Seoul National University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"HSG4112","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Glaceum","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glaceum \/ Kyungpook National University Hospital | Seoul National University Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Glaceum \/ Kyungpook National University Hospital | Seoul National University Hospital"},{"orgOrder":0,"company":"Glaceum","sponsor":"Seoul National University Hospital | Kyungpook National University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"HSG4112","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Glaceum","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glaceum \/ Seoul National University Hospital | Kyungpook National University Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Glaceum \/ Seoul National University Hospital | Kyungpook National University Hospital"},{"orgOrder":0,"company":"Glaceum","sponsor":"Seoul National University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"HSG4112","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Glaceum","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glaceum \/ Seoul National University Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Glaceum \/ Seoul National University Hospital"},{"orgOrder":0,"company":"Glaceum","sponsor":"Seoul National University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"HSG4112","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Glaceum","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glaceum \/ Seoul National University Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Glaceum \/ Seoul National University Hospital"}]

    Find Clinical Drug Pipeline Developments & Deals by Glaceum

    Menu

    Glaceum

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Glaceum

                            South Korea arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Glaceum

                            South Korea arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vutiglabridin

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase II

                            Sponsor : Seoul National University Hospital | Seoul National University Bundang Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Assess the Efficacy and Safety of Vutiglabridin in Knee Osteoarthritis Patients

                            Details : Vutiglabridin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Osteoarthritis, Knee.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 25, 2025

                            Lead Product(s) : Vutiglabridin

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase II

                            Sponsor : Seoul National University Hospital | Seoul National University Bundang Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Glaceum

                            South Korea arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Glaceum

                            South Korea arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vutiglabridin

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Catholic University of Korea | Kyunghee University Medical Center | Korea University Guro Hospital | Samsung Medical Center | Severance Hospital | Inje University | Hallym University Medical Center | The Catholic University of Korea Uijeongbu St.Marys Hos

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Assess the Efficacy and Safety of Vutiglabridin in Early Parkinson's Disease Patients

                            Details : Vutiglabridin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Parkinson Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 25, 2024

                            Lead Product(s) : Vutiglabridin

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Catholic University of Korea | Kyunghee University Medical Center | Korea University Guro Hospital | Samsung Medical Center | Severance Hospital | Inje University | Hallym University Medical Center | The Catholic University of Korea Uijeongbu St.Marys Hos

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Glaceum

                            South Korea arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Glaceum

                            South Korea arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HGR4113

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I

                            Sponsor : Seoul National University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Investigate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics and Food Effe...

                            Details : HGR4113 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus, Type 2.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 08, 2022

                            Lead Product(s) : HGR4113

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I

                            Sponsor : Seoul National University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Glaceum

                            South Korea arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Glaceum

                            South Korea arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HSG4112

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase I

                            Sponsor : Seoul National University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Investigate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics and Food Effe...

                            Details : HSG4112 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Obesity.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            April 04, 2022

                            Lead Product(s) : HSG4112

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase I

                            Sponsor : Seoul National University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Glaceum

                            South Korea arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Glaceum

                            South Korea arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HSG4112

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase II

                            Sponsor : Gangnam Severance Hospital | Seoul National University Bundang Hospital | Korea University Anam Hospital | Seoul National University Hospital | SMG-SNU Boramae Medical Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate the Safety and Efficacy of HSG4112 in Overweight and Obese Patients

                            Details : HSG4112 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Obesity.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            January 19, 2022

                            Lead Product(s) : HSG4112

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase II

                            Sponsor : Gangnam Severance Hospital | Seoul National University Bundang Hospital | Korea University Anam Hospital | Seoul National University Hospital | SMG-SNU Boramae Medical Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Glaceum

                            South Korea arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Glaceum

                            South Korea arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HSG4112

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase I

                            Sponsor : Seoul National University Hospital | Kyungpook National University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Investigate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics, and Food Eff...

                            Details : HSG4112 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Obesity.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            February 01, 2021

                            Lead Product(s) : HSG4112

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase I

                            Sponsor : Seoul National University Hospital | Kyungpook National University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Glaceum

                            South Korea arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Glaceum

                            South Korea arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HSG4112

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase I

                            Sponsor : Seoul National University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Investigate the Effect of Food on the Pharmacokinetics of HSG4112

                            Details : HSG4112 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Obesity.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            February 01, 2021

                            Lead Product(s) : HSG4112

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase I

                            Sponsor : Seoul National University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Glaceum

                            South Korea arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Glaceum

                            South Korea arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HSG4112

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase I

                            Sponsor : Kyungpook National University Hospital | Seoul National University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Investigate the Safety and Pharmacokinetic/Pharmacodynamic Characteristics of HSG4112

                            Details : HSG4112 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Obesity.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            January 11, 2021

                            Lead Product(s) : HSG4112

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase I

                            Sponsor : Kyungpook National University Hospital | Seoul National University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth